Understanding how drugs can form harmful attachments to proteins in the body
Identification and quantification of drug-protein adducts by mass spectrometry
This study is looking at how some medications can stick to proteins in the body and cause harmful side effects, and it aims to find better ways to detect these issues so we can make medicines safer for everyone.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10877040 on NIH RePORTER |
What this research studies
This research focuses on identifying and measuring how certain drugs create harmful attachments, known as adducts, to proteins in the body, which can lead to adverse drug reactions. By using advanced proteomic techniques, the researchers aim to develop reliable methods for detecting these drug-protein adducts in biological samples. The study will involve testing known drugs that have previously caused adverse events to better understand their effects on human health. This work is crucial for improving drug safety and minimizing the risks associated with new medications.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have experienced adverse drug reactions or are at risk of such reactions due to their medication regimen.
Not a fit: Patients who are not currently taking medications that are known to form reactive metabolites may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer medications by providing insights into how drugs can cause harmful reactions in patients.
How similar studies have performed: Previous research has shown promise in identifying drug-protein interactions, but this approach aims to provide a more comprehensive and quantitative understanding, making it a novel effort in the field.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Isoherranen, Nina — University of Washington
- Study coordinator: Isoherranen, Nina
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.